A new article in Chatelaine magazine highlights the latest developments in the fight against food allergies, providing national exposure for AllerGen investigators, trainees, partner organizations and AllerGen-supported food allergy research.
“How Close Are We to a Cure for Food Allergies?” published online this week, features interviews with researchers from AllerGen’s Canadian Food Allergy Strategic Team (CanFAST) and National Food Allergy Strategy (NFASt) legacy initiative, including:
- Dr. Susan Waserman (McMaster University);
- Dr. Moshe Ben-Shoshan (McGill University);
- Dr. Bruce Mazer (McGill University);
- Dr. John Gordon (University of Saskatchewan); and
- Dr. Edmond Chan (The University of British Columbia).
The article looks at current and emerging food allergy treatments and preventative strategies, such as oral immunotherapy (OIT), allergy patches and oral capsules, and dendritic cell modifications.
CanFAST food allergy prevalence findings and results from AllerGen’s CHILD Study, including AllerGen trainee Maxwell Tran’s research on the importance of introducing allergenic foods early, provide data to benchmark the scope of, and highlight issues relating to, the problem of food allergy in Canada.
Dr. David Fischer, President of the Canadian Society of Allergy and Clinical Immunology (CSACI), an AllerGen legacy partner, also comments in the article on the importance of new treatments to reduce the risk of “catastrophic accidental exposure” to ingested food allergens.